Urinary estrogen metabolites and prostate cancer : a case-control study and meta-analysis by M. Barba et al.
BioMed Central
Journal of Experimental & Clinical 
Cancer Research
ssOpen AcceReview
Urinary estrogen metabolites and prostate cancer: a case-control 
study and meta-analysis
Maddalena Barba1, Li Yang2, Holger J Schünemann1,3,4, Francesca Sperati1, 
Sara Grioni5, Saverio Stranges6, Kim C Westerlind7, Giovanni Blandino8, 
Michele Gallucci9, Rossella Lauria10, Luca Malorni10,11 and Paola Muti*12
Address: 1Department of Epidemiology, National Cancer Institute Regina Elena, Rome, Italy, 2Department of Environmental, Agricultural and 
Occupational Health, College of Public Health, University of Nebraska Medical Center, Omaha, Nebraska, USA, 3Department of Medicine, State 
University of New York at Buffalo, Buffalo, New York, USA, 4Department of Clinical Epidemiology and Biostatistics, McMaster University, 
Hamilton, Ontario, Canada, 5Nutritional Epidemiology Unit, National Cancer Institute, Milan, Italy, 6Health Sciences Research Institute, Warwick 
Medical School, Coventry, UK, 7Division of Endocrinology, Metabolism & Diabetes, University of Colorado at Denver and Health Sciences Center, 
Denver, Colorado, USA, 8Translation Oncogenomics Unit/Lab B, National Cancer Institute Regina Elena, Rome, Italy, 9Department of Urology, 
National Cancer Institute Regina Elena, Rome, Italy, 10Division of Medical Oncology, Department of Molecular and Clinical Endocrinology and 
Oncology, University of Naples Federico II, Naples, Italy, 11Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas, USA 
and 12Scientific Direction, National Cancer Institute Regina Elena, Rome, Italy
Email: Maddalena Barba - maddalena.barba@gmail.com; Li Yang - liyang@unmc.edu; Holger J Schünemann - hjs@buffalo.edu; 
Francesca Sperati - sperati@ifo.it; Sara Grioni - Sara.grioni@istitutotumori.mi.it; Saverio Stranges - S.Stranges@warwick.ac.uk; 
Kim C Westerlind - Kim.Westerlind@uchsc.edu; Giovanni Blandino - blandino@ifo.it; Michele Gallucci - gallucci@ifo.it; 
Rossella Lauria - rossellalauria@yahoo.it; Luca Malorni - malorni@bcm.edu; Paola Muti* - muti@buffalo.edu
* Corresponding author    
Abstract
Objective: To investigate prostate cancer (Pca) risk in relation to estrogen metabolism, expressed as urinary 2-hydroxyestrone
(2-OHE1), 16α-hydroxyestrone (16α-OHE1) and 2-OHE1 to 16α-OHE1 ratio.
Methods: We conducted a case-control study within the Western New York Health Cohort Study (WNYHCS) from 1996 to
2001. From January 2003 through September 2004, we completed the re-call and follow-up of 1092 cohort participants. Cases
(n = 26) and controls (n = 110) were matched on age, race and recruitment period according to a 1:4 ratio. We used the
unconditional logistic regression to compute crude and adjusted odds ratios (OR) and 95% confident interval (CI) of Pca in
relation to 2-OHE1, 16αOHE1 and 2-OHE1 to 16α-OHE1 by tertiles of urine concentrations (stored in a biorepository for an
average of 4 years). We identified age, race, education and body mass index as covariates. We also conducted a systematic
review of the literature which revealed no additional studies, but we pooled the results from this study with those from a
previously conducted case-control study using the DerSimonian-Laird random effects method.
Results: We observed a non-significant risk reduction in the highest tertile of 2-OHE1 (OR 0.72, 95% CI 0.25-2.10). Conversely,
the odds in the highest tertile of 16α-OHE1 showed a non-significant risk increase (OR 1.76 95% CI 0.62-4.98). There was a
suggestion of reduced Pca risk for men in the highest tertile of 2-OHE1 to 16α-OHE1 ratio (OR 0.56, 95% CI 0.19-1.68). The
pooled estimates confirmed the association between an increased Pca risk and higher urinary levels of 16α-OHE1 (third vs. first
tertile: OR 1.82, 95% CI 1.09-3.05) and the protective effect of a higher 2-OHE 1 to 16α-OHE1 ratio (third vs. first tertile: OR
0.53, 95% CI 0.31-0.90).
Conclusion: Our study and the pooled results provide evidence for a differential role of the estrogen hydroxylation pathway
in Pca development and encourage further study.
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Prostate cancer (Pca) is the most frequently diagnosed
malignancy and the second leading cause of cancer death
among men in Western countries [1]. Notwithstanding
the importance of this tumor, its causes remain largely
unknown. Age, family history, race and country of resi-
dence are the only established risk factors, but they
explain only a small proportion of Pca incidence [2].
A considerable number of studies have addressed prostate
sensitivity to androgens in relation to outcomes varying
from normal prostate growth to benign and malignant
diseases [3-5]. However, the role played by estrogens in
the pathogenesis of a wide spectrum of prostate physio-
logic and pathologic conditions is drawing increasing
attention [6]. In regards to Pca, experimental data from
studies conducted in Noble (NBL) rats strongly suggest a
critical role for estrogens in prostate carcinogenesis.
Indeed, in NBL rats chronically treated with testosterone,
the addition of estrogens is associated with a 100% inci-
dence of prostate adenocarcinomas, whereas the adminis-
tration of testosterone as a single agent produces Pca in
approximately 30 to 40% of treated animals [7,8]. The
estradiol plus testosterone treatment also induces acinar
lesions that are similar to human prostatic intraepithelial
neoplasia, a well recognized pre-invasive stage of adeno-
carcinoma [9].
Evidence is also mounting regarding the contribution of
hydroxylated metabolites of estrone (E1) and estradiol
(E2) to the overall estrogenic activity. The mutually exclu-
sive hydroxylation of E1 and E2 at positions C-16α or C-
2 leads to the production of either biologically active
estrogens (16α-hydroxyestrone/estradiol) or derivatives
with virtually no estrogenic activity (2-hydroxyestrone/
estradiol), respectively [10-12]. The different profiles in
terms of biological activity and genotoxic properties
might have consequences in terms of Pca risk.
However, the overall body of evidence remains particu-
larly limited when considering estrogen metabolites in
relation to Pca risk. Our prior case-control study, con-
ducted in Buffalo, NY, suggested an increased risk of clin-
ically evident Pca in men with a lower 2-OHE1/16α-
OHE1 ratio [13]. Similar results from studies evaluating
breast cancer, as another hormone-dependent tumor,
support this observation [14-18].
In the current case-control study, we have further tested
the hypothesis that the pathway favoring 2-hydroxylation
over 16α-hydroxylation is associated with a reduction in
Pca risk. We also conducted a systematic review of the lit-
erature to evaluate the totality of the evidence of this
research question.
Material and methods
From 1996 to 2001, 1961 men were enrolled in the West-
ern New York Health Cohort Study (WNYHCS). A
detailed description of the WNYHCS study design, meth-
ods and participants' characteristics is available elsewhere
[14].
In brief, all participants provided informed consent; the
Human Subjects Review Board of the University at Buf-
falo, School of Medicine and Biomedical Science
approved procedures for protection of human subjects in
the study. At the time of recruitment, trained interviewers
collected extensive data on demographics and life style
during in-person interviews. The use of a standardized
protocol allowed for the collection of anthropometric
data. The study participants donated morning spot urine
which was kept at -80°C until biochemical determina-
tions.
From January 2003 through September 2004, we com-
pleted the Western New York Health Cohort (WNYHC)
re-call and follow-up. For the purposes of the present case-
control study (PROMEN II study), the re-call process
included male participants who met the following inclu-
sion criteria: age at recruitment between 50 and 85, base-
line history negative for malignancies, cardiovascular
diseases and clinically defined type-2 diabetes. On this
basis, the re-call and follow-up process involved 1092
cohort participants. Among them, 52 were not eligible for
medical reasons other than Pca, 46 had died from causes
other than Pca, 22 had moved out of Erie and Niagara
Counties, and 117 were not able to be contacted by mail
or phone. Among the remaining 855 study participants,
232 refused to join the study, 40 were scheduled but can-
celled the appointment and 8 were still in-course of
assessment at the end of the follow-up period. In this
group of non-participating subjects, all of the cohort
members referred to being free from Pca in their tele-
phone interviews. Thus, 575 participants joined the study,
accounting for an overall participation rate of 67% (575/
855).
Pca cases were men who had been diagnosed with inci-
dent, histologically confirmed Pca within the time-frame
between their recruitment in the WNYHC and the end of
the follow-up period. Identifying Pca cases was based on
the participants' reports at the re-call, which was subse-
quently validated by clinical records provided by their
urologists. We identified and validated a total number of
41 incident prostate cancer cases. The 534 control subjects
were male members of the WNYHC who, based on their
report, were free from clinically evident Pca at the time of
diagnosis of the related case. The control status was vali-
dated with a serum PSA assessment on a blood sample
donated at the time of recall. We used a PSA cut-off valuePage 2 of 8
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level was higher than 4 ng/ml, we ultimately included in
the control group only those who tested negative at the
prostate biopsy. We requested and obtained the pertinent
medical records from the urologists.
For each case, four control subjects were randomly chosen
after matching for age (within a 3-year-range), race and
date of recruitment. The independent variables of interest,
namely 2-OHE1, 16α-OHE1 and the 2-OHE1 to16α-
OHE1 ratio, were available for 110 controls and 26 cases,
thus we conducted the present analysis on 136 subjects.
Hormonal Determinations
For standardization purposes, we collected morning spot
urine between 7:00 a.m. and 9:00 a.m. from all partici-
pants. We then transferred the aliquoted urine samples to
the Eppley Institute, University of Nebraska Medical
Center (UNMC), and stored them at -80°C until analysis.
Each sample was thawed only once prior to analysis. We
handled urine samples identically and located them in the
laboratory runs randomly. All laboratory personnel were
blinded in regards to case-control status. All of the study
samples were analyzed in duplicate. Two-milliliter aliq-
uots of urine were partially purified throughout solid
phase extraction (SPE) with a phenyl cartridge (Varian,
Palo, Alto, CA) and ultra-performance liquid chromatog-
raphy/tandem mass spectrometry (LC/MS-MS). Analytes
were identified based on their retention time and tandem
mass spectrometry. Standards of the catechol estrogens 2-
OHE1(E2) and 16α-OHE1(E2) were purchased from Ster-
aloids Inc. (Newport, RI).
To avoid the artifacts and errors introduced by maintain-
ing the urine samples at 37°C for 8 hours, we carried out
all the analyses without glucuronidase/sulfatase treat-
ment. We adjusted urine samples to pH 7 with 1 M NaOH
or 1 M HCl.
We performed the LC/MS analyses through a Waters
Acquity ultra-performance liquid chromatography
(UPLC) system connected with a high performance Quat-
tro Micro triple quadruple mass spectrometer designed for
LC/MS-MS operation. We performed the analytical sepa-
rations on the UPLC system using an Acquity UPLC BEH
C18 1.7 μm column (1 × 100 mm) at a flow rate of 0.15
ml/min. We then moved the elutions from the UPLC col-
umn to the Quattro Micro mass spectrometer.
The ionization method used for MS analysis was Electro-
spray ionization (ESI) in both the positive ion (PI) and
negative ion (NI) mode with an ESI-MS capillary voltage
of 3.0 kV, an extractor cone voltage of 3 V, and a detector
voltage of 650 V. We performed the MS-MS in the multi-
ple reaction monitoring (MRM) mode to produce struc-
tural information about the analytes by fragmenting the
parent ions inside the mass spectrometer and identifying
the resulting daughter/fragment ions. We processed the
resulting data and quantified the estrogen metabolites
using the QuanLynx software (Waters).
To calculate limits of detection, we injected various con-
centrations of the analytes to LC/MS-MS. The detection
limit was considered to be the injected amount that
resulted in a peak with a height at least two or three times
higher than the baseline. The detection limits of 2-OHE1
and 16α-OHE1 were 18 fmol and 349 fmol, respectively.
Intra-assay coefficients of variation for 2-OHE1 and 16α-
OHE1 were 3.2% and 3.0%, respectively. Inter-assay coef-
ficients of variation were 1.9% and 3.5%, respectively.
We had previously measured the intra- and inter-individ-
ual variability for 2-OHE1, 16α-OHE1 determinations
and their ratio over a one year period [13]. The intra-class
correlation coefficients (ICCs) and lower limit of 95% CI
(in parentheses) were 0.70 (0.46), 0.63 (0.35) and 0.78
(0.62), respectively. We had previously provided a
detailed description of the procedures related to the relia-
bility assessment [13].
Systematic Review
We conducted a systematic search of the literature to iden-
tify additional studies published up to August 2009 which
examined the association between estrogen metabolites
and Pca risk using our standard methods [19-22]. We
searched MEDLINE (January 1966 onwards) and EMBASE
(January 1980 onwards). An expert librarian designed a
search strategy combining terms for estrogens, estrogen
metabolites and prostate specific antigen (PSA) with
terms for Pca (available upon request). We screened titles
and abstracts in duplicate using the following inclusion
criteria: observational studies investigating prostate can-
cer risk in relation to estrogen metabolism. We included
studies providing at least one measure of either urinary or
circulating levels of 2-OHE1, 16α-OHE1 and the 2-OHE1
to 16α-OHE1 ratio.
Statistical analysis
We examined distributions for all variables of interest by
determining the frequencies, mean, median and measures
of variance. To evaluate the statistical significance of the
unadjusted associations between case/control status and
participants' characteristics, we used either Fisher's exact
tests or Pearson's chi-square tests for categorical variables.
The 2-OHE1 and 16-αOHE1 urinary levels were standard-
ized by total urinary creatinine. We used unconditional
logistic regression to compute crude and adjusted odds
ratios (OR) and 95% confident interval (CI) of Pca in rela-
tion to 2-OHE1, 16-αOHE1 and the ratio of 2-OHE1 toPage 3 of 8
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the same models to test for significance in trends of asso-
ciation for any of the independent variables. We com-
puted the cut-off points of the previously mentioned
tertiles based on the distributions of estrogen metabolites
in control subjects. We analyzed each independent varia-
ble separately. Based on the published literature, we iden-
tified age, race, education level, BMI and waist-to-hip ratio
as possible covariates and tested them using regression
models. Although none of them was a confounder for the
investigated associations, we included age in years in fur-
ther analyses based on its biological relevance in prostate
carcinogenesis [2].
We verified several sources of potential bias. Because the
exclusion of participants with missing data for any of the
two outcome variables could have introduced a source of
bias in our final sample, we examined data by subsets.
Each of the two datasets included men with no missing
data for either urinary levels of 2-OHE1 or 16-αOHE1. We
then examined by case-case and control-control compar-
ing the characteristics of the 136 subjects (110 controls
and 26 cases) with no data missing for any of the consid-
ered variables and those of the subjects (534 controls and
41 cases) who fulfilled our study eligibility criteria.
Finally, we compared the subjects in the latter category
[575] to the 517 original cohort members who did not
join the study either because they did not fulfil the inclu-
sion criteria, were lost to follow-up or were not willing to
participate.
To date, no data exists related specifically to any of these
three categories (i.e. co-morbidity data pertinent to the
WNYCS). Thus, we considered these 517 male subjects as
part of an overall, although heterogeneous, category. As
expected, the 517 males from the original cohort who did
not ultimately join our study showed statistically signifi-
cant differences when compared to the 575 included
study participants. We analyzed these data using SPSS ver-
sion 14.0 (SPSS, Inc., Chicago, IL).
Meta-analysis
We planned to combine the results from the current study
with those identified in the systematic review using the
DerSimonian-Laird random effects method expressing the
pooled estimates in terms of summary OR and 95% CI.
We calculated I2 to assess heterogeneity across study
results applying the following interpretation for I2 (J Hig-
gins, personal communication): 0-50 = low; 50-80 = mod-
erate and worthy of investigation; 80-100 = severe and
worthy of understanding; 95-100 = aggregate with major
caution [23]. We used Revman 5.0 for the meta-analysis
(Copenhagen: The Nordic Cochrane Centre, The
Cochrane Collaboration, 2008).
Results
Table 1 shows the descriptive characteristics of the study
participants. No significant differences emerge when com-
paring cases and controls by age, race, education, and
anthropometrics.
In Table 2, we report crude and age-adjusted Pca risk esti-
mates in relation to tertiles of urinary estrogen metabo-
lites and their ratio. The OR in the highest compared to
the lowest tertile of 2-OHE1 was 0.72 (95% CI 0.25-2.10).
Conversely, the odds in the highest tertile of 16α-OHE1
was 1.76 (95% CI 0.62-4.98). Finally, the 2-OHE1 to 16α-
OHE1 ratio showed a non-significant risk reduction
Table 1: Participants Descriptive Characteristics by Case-
Control Status, PROMEN Study, 1996-2001
Prostate Cancer
Control Case two-tails
n % n % p-value
110 80.88 26 19.12
Age
50-59 31 28.20 7 26.90
60-69 40 36.40 9 34.60
70-79 39 35.50 10 38.50
0,902
Race
Black 4 3.60 1
White 106 96.0 25
1.000
Years of Education
8-13 66 60.00 16 61.50
14-18 44 40.00 10 38.50
1.00
BMI
≤ 25 25 22.90 6 23.10
25-30 55 50.50 11 42.30
≥ 30 29 26.60 9 34.60
0.683
Waist circumference
≤ 97,50 56 51.40 10 38.50
> 97,50 53 48.60 16 61.50
0.279
Hip circumference
≤ 102,50 56 51.40 12 46.20
> 102,50 53 48.60 14 53.80
0.668
Waist to hip ratio
≤ 0,95 55 50.50 14 56.00
> 0,95 54 49.50 11 44.00
0.662
*BMI: body mass index expressed as weight in kilograms divided by 
the square of height in meters (kg/m2)Page 4 of 8
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tertile). When we tested the independent variables of
interest for significance in trends of associations, none of
the models produced significant results.
Analyzing data by subsets including only one of the two
outcome variables did not affect the study results at any
level. From the case-case and control-control comparison,
no significant differences emerged between the partici-
pants who had been included in the present analyses and
those who had been excluded because of missing data
items.
Results of the systematic review
Our search of the literature yielded a total of 289 unique
citations. Based on the titles and abstracts screening of the
retrieved citations, only our previously conducted case-
control study [13] and the study from Yang and colleagues
[24] met the eligibility criteria. Unfortunately, we could
not include the latter manuscript in our meta-analysis. In
the study from Yang et al the whole control group, which
itself represents the vast majority of the overall sample
(118/139), is part of the Western New York Health Cohort
and directly stems from the recall process carried out
between January 2003 and September 2004 as part of the
PROMEN II study. The inclusion of this study would arti-
ficially inflate the size of our meta-analysis and poten-
tially bias our results. Thus, only another study, namely
our previously conducted case-control study, was
included in our meta-analysis.
Figure 1. shows the results of the meta-analysis results.
The pooled data are based on 122 Pca patients and 414
controls. The meta-analysis suggested an association
between an increased Pca risk and higher urinary levels of
16α-OHE1 (third vs. first tertile: OR 1.82, 95% CI 1.09-
3.05) and the protective effect of a higher 2-OHE 1to16α-
OHE1 ratio (third vs. first tertile: OR 0.53, 95% CI 0.31-
0.90). We found no statistically significant results for 2-
OHE1. There was no evidence of heterogeneity (I2 = 0, for
any of the reported estimates).
Discussion
The results of this study and meta-analysis suggest that the
metabolic pathway favoring 2-hydroxylation over 16α-
hydroxylation might be associated with a reduction in Pca
risk. While the findings from this case-control study are
not statistically significant, they appear consistent with
those from a previously conducted, larger case-control
study on the protective role of hydroxylated metabolites
with virtually no estrogenic activity in the development of
Pca [13]. A meta-analysis of the results from these two
studies, preceded by a systematic search of the literature
showing no additional studies, revealed evidence in sup-
port of the study hypothesis.
Our study has several strengths. The prospective design
allowed for sample collection years before Pca diagnosis.
On this basis, it is plausible that the observed differences
in urinary levels of estrogen metabolites by case-control
status were not biased by any cancer-related hormonal
Table 2: Crude and Adjusted Prostate Cancer Risk Estimates
Cs/Coa Crude ORb 95% CIc Adjusted ORd 95% CIc
2OHE1
1st tertile ≤ 0.21 10/37 1 - - -
2nd tertile 0.21 - 2.26 9/37 0.90 0.33 -2.47 0.90 0.32-2.46
3rd tertile > 2.26 7/36 0.72 0.25 -2.10 0.69 0.23-2.03
trend 0.85 0.50-1.44 0.83 0.49-1.42
P for trend 0.55 0.50
16OHE1
1st tertile ≤ 61.84 7/37 1 - - -
2nd tertile 61.84 - 158.74 7/37 1.00 0.32 - 3.13 1.00 0.32-3.13
3rd tertile >158.74 12/36 1.76 0.62 - 4.98 1.73 0.58-5.14
trend 1.35 0.80-2.30 1.33 0.76-2.33
P for trend 0.26 0.31
2OHE1/16OHE1
1st tertile ≤ 0,31 11/37 1 - -
2nd tertile 0.31-1.64 9/37 0.82 0.30-2.21 0.80 0.30-2.17
3rd tertile > 1.64 6/36 0.56 0.19 - 1.68 0.57 0.19-1.71
trend 0.75 0.44-1.29 0.76 0.44-1.30
P for trend 0.30 0.31
a matched on age, race and recruitment period
b odds ratio; c95% confidence interval; dadjusted for agePage 5 of 8
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term effects of cryopreservation represent a potential
source of variability because of the occurrence of sample
degradation, but data from a previously conducted pro-
spective study showed stability of estrogen metabolites
over time [16]. However, if any effect from degradation
exists, it should be similar for cases and controls because
of the matching for date at recruitment. At the time of the
WNYHC recall, we tested control subjects for a potential
presence of latent prostate cancer by serum analysis for
PSA and, for those men whose PSA value exceeded the
pre-defined cut-off, by prostate biopsy. This approach
increases our confidence in the case-control definition
and reduces the possibility for misclassification bias. We
adopted several strategies to control for potential sources
of hormone variability. In conducting the WNYHC
recruitment and recall, we applied inclusion criteria
requiring the absence of pathologic conditions altering
hormone metabolism (i.e. type 2 diabetes). We observed
highly standardized conditions at sample collection, han-
dling and assaying. All hormone determinations were per-
formed at the end of the study, to reduce technical
variability. We also evaluated the intra-individual varia-
bility of 2-OHE1, 16αOHE1 and their ratio in a previously
conducted study [13]. The resulting intra-class correlation
coefficients (ICC) indicated high reliability, thus reducing
the chance that a measurement error might have affected
the study results to a significant extent.
Our study also has several limitations. The sample size
was very small, especially for cases, and none of the pro-
vided estimates reached statistical significance in the orig-
inal study. The small sample size might have limited our
ability to detect the investigated associations. Selection
bias is another source of possible concern for several rea-
sons. First, the participation rate was quite low (67%) and
unfortunately we had limited information allowing a
comparison between participating and non-participating
subjects. Indeed, the lack of mortality or co-morbidity
data prevented us from characterizing those members of
the original cohort who were excluded because of diseases
other than Pca or death. The final comparison between
the 575 men who joined the study and the 517 cohort
members who did not show significant differences. The
exclusion of participants with missing data either for any
of the outcome variables or any of the considered varia-
Pooled estimates of Prostate Cancer Risk in relation to Estrogen MetabolitesFigure 1
Pooled estimates of Prostate Cancer Risk in relation to Estrogen Metabolites.
Outcome: 2-OHE1/16alphaE1 ratio 
 Muti, 2002       27/106             37/96  77.86      0.54 [0.30, 0.99] 
 Barba, 2009        6/36              11/37  22.14      0.47 [0.15, 1.46] 
Total (95% CI) 142                133 100.00      0.53 [0.31, 0.90]
Total events: 33 (3rd tertile), 48 (1st tertile)
Test for heterogeneity: Chi² = 0.05, df = 1 (P = 0.83), I² = 0%
Test for overall effect: Z = 2.36 (P = 0.02)
 0.1  0.2  0.5  1  2  5  10
 Favours 3rd tertile  Favours 1st tertile
Outcome: 16 alpha E1 
 Muti, 2002       41/92              32/101  77.04      1.73 [0.96, 3.12] 
 Barba, 2009       12/36               7/37  22.96      2.14 [0.73, 6.28] 
Total (95% CI) 128                138 100.00      1.82 [1.09, 3.05]
Total events: 53 (3rd tertile), 39 (1st tertile)
Test for heterogeneity: Chi² = 0.12, df = 1 (P = 0.73), I² = 0%
Test for overall effect: Z = 2.28 (P = 0.02)
Review: PROMEN II
Comparison:
2-OHE1Outcome:
3rd tertile vs 1st tertile 
Study  3rd tertile  1st tertile
 OR (random)
 Weight
 OR (random)
 n/N  n/N
 Muti, 2002       29/104             33/100  77.16      0.79 [0.43, 1.43] 
 Barba, 2009        7/36              10/37  22.84      0.65 [0.22, 1.96] 
Total (95% CI) 140                137 100.00      0.75 [0.45, 1.27]
Total events: 36 (3rd tertile), 43 (1st tertile)
Test for heterogeneity: Chi² = 0.09, df = 1 (P = 0.77), I² = 0%
Test for overall effect: Z = 1.06 (P = 0.29)Page 6 of 8
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Neither the analyses conducted by subsets including only
one of the outcome variables, nor the analyses performed
by case-case and control-control comparison between
subject with and without missing data items showed sig-
nificant results.
We conducted a systematic search of the literature and
combined the available results in a meta-analysis. We
found significant evidence supporting the protective role
of the metabolic pathway favoring 2-hydroxylation over
16α-hydroxylation in Pca development. This increases
our confidence in the single studies' results, which were
consistent, and might indicate that the lack of significance
was mainly due to the limited sample size of the single
studies.
Despite their historical use in prostate cancer treatment,
our knowledge regarding the effects of estrogens on pros-
tate, their role in cancer development and the mecha-
nisms mediating their action as therapeutic agents is quite
limited. The published literature mainly focuses on the
effects of circulating estrone and estradiol in relation to
prostate cancer risk, providing inconsistent evidence
[17,18,25,26]. A wide variety of methodological issues
ranging from the restricted sample size to possible bias
introduced by uncontrolled sources of hormonal variabil-
ity might provide a partial explanation to the cited incon-
sistency. It is also plausible that the surmised exposures
have not been captured over periods comparable by
degree of prostate sensitivity to hormonal influences
across the different studies. The lack of consideration for
factors potentially relevant to the overall estrogenic activ-
ity, namely, hydroxylated metabolites of E1 and E2, might
provide a further explanation that would integrate the
aforementioned hypotheses.
The dominating hydroxylation pathway significantly
affects the biological activity of estrogen metabolites.
Indeed, 16α-OHE1 binds with high affinity the estrogen
receptor and exerts a strong estrogenic action that leads to
increased cell proliferation and DNA synthesis [27,28].
Conversely, 2-OHE1 exerts a weak agonist effect on the
oestrogen receptor and shows anti-angiogenic properties
[29,30].
Little epidemiologic evidence exists with regard to the
hypothesis investigated in the present study. Our previous
study results support the association between elevated 2-
OHE1 urinary levels and a reduced Pca risk (OR 0.83 95%
CI 0.43-12.44), whereas elevated16α-OHE1 urinary levels
are associated with increased risk (OR 1.69 95% CI 0.93-
3.06, p for linear trend 0.002) [13]. In their case-control
study, Yang and colleagues found no significant difference
in the median levels of 2-OHE1 and 16α-OHE between
the compared groups. However, the sample size was very
limited and the number of cases extremely low [24]. In
their cross-sectional study, Teas et al evaluated the varia-
bility of the urinary levels of 2-OHE1 and 16αOHE1 in a
sample of African-American men attending prostate can-
cer screening clinics and investigated any possible relation
of these two metabolites with PSA. They reported an over-
all significant reduction in 2-OHE1 per each 1.0 ng/ml
increase in PSA [31].
Further evidence of the role of sex steroid hormones in
prostate cancer emerges from studies focusing on the role
played by estrogen metabolites in breast carcinogenesis.
Several case-control and cohort studies show that women
who metabolize a larger proportion of estrogens via the
16α-hydroxy pathway may be at a significantly higher risk
of breast cancer compared to women who metabolize
proportionally more estrogens via the 2-hydroxy pathway
[16,32-34]. We observed a 40% breast cancer risk reduc-
tion in women whose 2-hydroxyestrone (2-OHE1) to
16α-hydroxyestrone ratio was in the highest tertile of the
distribution compared to those in the lowest tertile [35].
In summary, in the context of a still limited scientific evi-
dence base, our study and meta-analysis provide data sup-
porting a differential role of the estrogen hydroxylation
pathway in prostate cancer development. The small sam-
ple size of our original study prevents us from drawing
strong conclusions, but the results of our meta-analysis
including the second study provide us with greater evi-
dence in support of the investigated association and the
need for further studies.
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